TEVA Latest Headlines

J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)

at www.tipranks.com (Thu, 5-Nov 4:15 AM)

Teva’s Strong Execution and Growth Momentum Drive Buy Rating as Price Target Rises to $54

at www.tipranks.com (Wed, 4-Nov 8:15 AM)

Teva (TEVA) Gets a Buy from Scotiabank

at www.tipranks.com (Wed, 4-Nov 4:26 AM)

Teva Earnings Call Signals Stronger Growth Ahead

at www.tipranks.com (Tue, 3-Nov 7:19 PM)

Teva to buy U.S. rights to two Samsung Bioepis biosimilars

at seekingalpha.com (Tue, 3-Nov 9:16 AM)

Teva raises 2026 outlook on strength of innovative brands

at seekingalpha.com (Tue, 3-Nov 7:58 AM)

Teva raises 2026 outlook for AUSTEDO, AJOVY and UZEDY after strong Q3 growth

at seekingalpha.com (Tue, 3-Nov 7:24 AM)

Teva halts a 350-patient Phase 2 MSA study after interim futility readout, with no safety issues flagged

Market Chameleon (Mon, 2-Nov 8:19 AM)

Teva Pharmaceutical Industries Limited Q3 2026 Earnings Preview

at seekingalpha.com (Mon, 2-Nov 10:02 AM)

Teva discontinues Phase 2 study of Emrusolmin in multiple system atrophy

at seekingalpha.com (Mon, 2-Nov 8:17 AM)

Teva Gains After FDA Clears WELTRUZA as the First Once-Monthly Subcutaneous Olanzapine for Adult Schizophrenia

Market Chameleon (Fri, 9-Oct 11:33 AM)

Teva Wins FDA Approval for WELTRUZA, a Once-Monthly Subcutaneous Olanzapine That Requires No Post-Injection Monitoring

Market Chameleon (Fri, 9-Oct 7:35 AM)

Teva Sets Nov. 3 Q3 2026 Results Call, Putting 8:00 a.m. ET on Investors’ Calendars

Market Chameleon (Thu, 24-Sep 8:42 AM)

FDA Grants Priority Review for Teva’s Ecopipam: A Decade-First Therapy Could Redefine Tourette Syndrome Care

Market Chameleon (Wed, 19-Aug 8:54 AM)